Tricida
Stage
IPO | IPOTotal Raised
$177.5MDate of IPO
6/28/2018Market Cap
0.01BStock Price
0.01Missing: Tricida's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Tricida's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Tricida
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Tricida is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
1,568 items
Tricida Patents
Tricida has filed 22 patents.
The 3 most popular patent topics include:
- Kidney diseases
- Equilibrium chemistry
- Electrolyte disturbances
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/5/2017 | 8/9/2022 | Kidney diseases, Nephrology, Electrolyte disturbances, Rare diseases, Equilibrium chemistry | Grant |
Application Date | 5/5/2017 |
|---|---|
Grant Date | 8/9/2022 |
Title | |
Related Topics | Kidney diseases, Nephrology, Electrolyte disturbances, Rare diseases, Equilibrium chemistry |
Status | Grant |
Latest Tricida News
Mar 1, 2023
New York, New York, UNITED STATES NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the ordinary shares of EQONEX LIMITED. EQONEX LIMITED ordinary shares were suspended on November 30, 2022, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Scopus BioPharma Inc. Scopus BioPharma Inc. common stock was suspended on December 19, 2022, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock and warrant of Peak Bio, Inc. Peak Bio, Inc.’s securities were suspended on January 10, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Statera Biopharma, Inc. Statera Biopharma, Inc. common stock was suspended on January 12, 2023, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Tricida, Inc. Tricida, Inc. common stock was suspended on January 24, 2023, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the Class A Common Stock, units, and warrants of Arbor Rapha Capital Bioholdings Corp. I. Arbor Rapha Capital Bioholdings Corp. I’s securities were suspended on January 24, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Calithera Biosciences, Inc. Calithera Biosciences, Inc.’s common stock was suspended on February 2, 2023, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Waitr Holdings Inc. Waitr Holdings Inc.’s common stock was suspended on February 2, 2023, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Allied Healthcare Products, Inc. Allied Healthcare Products, Inc.’s common stock was suspended on February 3, 2023, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Metacrine, Inc. Metacrine, Inc.’s common stock was suspended on February 9, 2023, and has not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delistings. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delisting and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly. For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series . -NDAQO-
Tricida Frequently Asked Questions (FAQ)
Where is Tricida's headquarters?
Tricida's headquarters is located at 7000 Shoreline Court, South San Francisco.
What is Tricida's latest funding round?
Tricida's latest funding round is IPO.
How much did Tricida raise?
Tricida raised a total of $177.5M.
Who are the investors of Tricida?
Investors of Tricida include Hercules Capital, OrbiMed Advisors, Sibling Capital, Limulus Venture Partners, Longitude Capital and 6 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.